CRMI Reports Sufficient Internal Controls After Governance Review
China Regenerative Medicine International Limited (CRMI) has reported that its internal control review, prompted by past non-compliance with GEM Listing Rules, has been positively assessed by an independent consultant. The consultant confirmed that CRMI's remedial measures are adequate, ensuring reliable governance and internal control systems. The Board and consultant will continue to oversee these systems for ongoing compliance.
China Regenerative Medicine International Limited (CRMI) has voluntarily disclosed the key findings of its internal control review, following previous issues of non-compliance with the GEM Listing Rules. An independent consultant has confirmed that CRMI’s remedial measures are sufficient and that the company now maintains reliable governance and internal control systems. The Board and consultant will continue to monitor these systems to ensure ongoing compliance. The original document can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRMI - China Regenerative Medicine International Limited published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
